Tracers / [177Lu]Lu-satoreotide
[177Lu]Lu-satoreotide
Also written as [Lu-177]Lu-satoreotide; [Lu-177]Lu-Satoreotide; Lu-177-Satoreotide
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- satoreotide tetraxetan (DOTA-conjugated somatostatin receptor antagonist peptide)
- Target / mechanism
- Somatostatin receptor 2 (SST2) antagonist PMID 36145306
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | above 97% | above 90% | satoreotide tetraxetan Octreopharm/Ipsen, Berlin, Germany | 36145306 2022 Pharmaceuticals (Basel) |
Need this precursor?We can point you to suppliers for [177Lu]Lu-satoreotide, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36145306: 'The peptide conjugate satoreotide tetraxetan was supplied by Octreopharm/Ipsen (Berlin, Germany)'.